GlassScriptPhysician profile
Benecia Tracee Williams
NPI 1841635265
$5,316.07
in general payments reported to CMS, 2019-2025
32 companies · $547 in 2025
The $547 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $605 · 2021: $608 · 2022: $979 · 2023: $756 · 2024: $865 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.67 | 2020-2025 | Botox, Ubrelvy |
| Merz Pharmaceuticals, LLC | $945.02 | 2021-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $479.57 | 2019-2025 | Dysport |
| Merz North America, INC. | $364.97 | 2019-2020 | |
| Allergan, INC. | $275.91 | 2019-2022 | |
| Nevro Corp. | $158.96 | 2019-2022 | |
| Saol Therapeutics INC. | $155.32 | 2019-2021 | |
| Medtronic USA, INC. | $151.74 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $149.83 | 2019-2022 | |
| Sage Therapeutics, LLC | $147.80 | 2021-2023 | |
| Piramal Critical Care | $141.51 | 2022-2025 | |
| Boston Scientific Corporation | $132.40 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.13 | 2022 | |
| Medtronic, INC. | $116.81 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $109.91 | 2019 | |
| Scilex Pharmaceuticals INC. | $66.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $64.57 | 2023 | Lyvispah |
| Lundbeck LLC | $45.06 | 2024-2025 | Vyepti |
| Microtransponder, INC. | $39.19 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $28.48 | 2019 | |
| Ibsa Pharma INC. | $26.76 | 2022 | |
| Baudax Bio INC. | $23.79 | 2021 | |
| Pylant Medical | $22.25 | 2020 | |
| Si-Bone, INC. | $19.46 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2023 | Nuedexta |
| Pacira Therapeutics, INC. | $17.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.43 | 2019 | |
| Neuros Medical, INC. | $16.66 | 2025 | Altius |
| Ossur Americas, INC. | $15.99 | 2025 | |
| Bioventus LLC | $14.19 | 2024 | L300 Go System |
| Orthofix Medical, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benecia Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.